On July 24, the U.S. House of Representatives passed a Defense Funding Bill that included $16 million in funding that is eligible to be awarded to mesothelioma research.
The House approved the fiscal year 2014 Defense Appropriations bill (H.R. 2397) on a vote of 315 to 109. The bill includs funding for the Congressionally Directed Medical Research Programs, including the Peer Reviewed Cancer Research Program in which mesothelioma is a topic area.
Each year, the Meso Foundation advocates to continue and increase this vital funding. As a result, $8.8 million dollars has been given to mesothelioma research to date. This is a victory in today’s tough economic climate.
For more information, read our earlier blog regarding this topic.
Last week, the Journal of Thoracic Oncology published the results of a study looking into the overexpression of the ephrin B2 receptor (EPHB2) in patients with mesothelioma. The researchers at the New York University Langone Medical Center observed that EPHB2 is overexpressed in all malignant mesothelioma cell lines, but not in benign mesothelial cells. In addition, they found that silencing this receptor resulted in a significant increase in certain processes responsible for naturally ridding the body of old and defective cells (including cancerous ones).
The team of researchers who worked on this study includes Dr. Harvey Pass, one of the founders and a former board member of the Mesothelioma Applied Research Foundation. Dr. Pass has been a leader in the field of mesothelioma and a vocal advocate for mesothelioma patients.
“The mesothelioma community is looking for novel targets for therapy, and the data on the ephrins may provide an opportunity for this,” said Dr. Pass. “Certainly we also must expand our findings to elucidate the prognostic and predictive characteristics of this important pathway,” he added.
Support future research efforts. Donate to the Mesothelioma Applied Research Foundation today.